The Ultegra rapid platelet function assay: Comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy

American Heart Journal

Volumn 143, Issue 4, 2002, Pages 602-611

  Wheeler, Guy L ^a   Braden, Gregory A ^a   Steinhubl, Steven R ^b   Kereiakes, Dean J ^c   Kottke Marchant, Kandice ^d   Michelson, Alan D ^e   Furman, Mark I ^e   Mueller, Michele N ^c   Moliterno, David J ^d   Sane, David C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WILFORD HALL MEDICAL CENTER   (United States)

^c Ohio Heart and Vascular Center   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB;

ADULT; ARTICLE; BINDING ASSAY; CLINICAL TRIAL; DEVICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FUNCTION TEST; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT MONITORING; PERFORMANCE; PRIORITY JOURNAL; RECEPTOR BINDING; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TURBIDIMETRY; UNITED STATES;

EID: 0036242793     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.121734     Document Type: Article

References (15)

1. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
2. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin and anti-platelet antibody Fab 7E3 in high risk coronary angioplasty
3. Point of care measured platelet inhibition correlates with the risk of an adverse cardiac event following percutaneous coronary intervention. Results of the GOLD (AU-Assessing Ultegra) multicenter study
4. Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial
5. Aggregation of blood platelets by adenine diphosphate and its reversal
6. Rapid and simple platelet function assay ta assess glycoprotein IIb/IIIa receptor blockade
7. Rapid platelet-function assay: An automated and quantitative cartridge-based method
8. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex
9. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GPIIb/IIIa therapy
10. Differential inhibition of platelet aggregation induced by adenosine diphosphate and thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for the inhibition of the internal pool of GPIIb/IIIa receptors
11. Randomized trial of a GPIIb/IIIa platelet receptor blocker
12. High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists
13. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyses (PFA-100) during percutaneous coronary intervention
14. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests. Relevance for monitoring long-term glycoprotein IIb/IIIa inhibition
15. Attainment and maintenance of platelet inhibition by standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention